Study Comparing Ritlecitinib Alone Versus Ritlecitinib Plus Narrowband UVB Light for Treating Vitiligo Over One Year

What this Trial Is About

Vitiligo affects about 1 to 2% of people worldwide and can greatly reduce quality of life. Researchers are studying how the drug ritlecitinib, which blocks certain enzymes involved in the immune response, works alone or combined with narrowband UVB light therapy to treat vitiligo. This study aims to compare the improvement in vitiligo severity on the face and body after 52 weeks between these two treatment approaches. Participants will be randomly assigned to receive either ritlecitinib 100 mg once daily by mouth alone or combined with narrowband UVB light therapy twice weekly for 52 weeks. After this period, all participants will continue taking ritlecitinib 100 mg daily in an open-label phase. The study will include patients with different skin types and vitiligo that is either active or stable. Treatment effects will be evaluated across these groups. Participants will attend eight study visits over about 72 weeks for assessments including skin evaluations, blood sample collection, and pregnancy tests every four weeks for women who can become pregnant. Some volunteers will have skin biopsies at baseline, week 4, and week 52. Researchers will measure changes in vitiligo severity using scoring indexes focused on the face and total body. Safety and quality of life will also be monitored throughout the study.

Combination Approach With Ritlecitinib and nbUVB Compared to Ritlecitinib Alone for Treating Vitiligo